Molecular profiling of prostate cancer.
Curr Urol Rep
; 5(1): 45-51, 2004 Feb.
Article
em En
| MEDLINE
| ID: mdl-14733837
ABSTRACT
The ability to distinguish between aggressive and nonaggressive tumors has not changed despite vast improvements in the detection of prostate cancer (PCA). To improve predictive accuracy, additional PCA-specific biomarkers must be identified and it is the emerging microarray technology and gene expression profiling that appear to be capable of achieving this goal. Through comparisons of a number of published microarray studies of PCA, several potential biomarkers appear on the horizon, including the serine protease Hepsin, a-methylacyl CoA racemase, and the human homologue of the Drosophila protein Enhancer of Zeste. Although these markers will move toward validation by eventual protein expression studies, another aspect of microarray expression, global signature expression patterns through multidimensional scaling, appears to be promising in distinguishing between aggressive and nonaggressive forms of PCA or in distinguishing PCA from benign prostatic hyperplasia or normal prostate tissue.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Análise de Sequência com Séries de Oligonucleotídeos
/
Perfilação da Expressão Gênica
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article